Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Herbrecht R, et al. Among authors: troke pf. N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191. N Engl J Med. 2002. PMID: 12167683 Free article. Clinical Trial.
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group. Patterson TF, et al. Clin Infect Dis. 2005 Nov 15;41(10):1448-52. doi: 10.1086/497126. Epub 2005 Oct 13. Clin Infect Dis. 2005. PMID: 16231256 Clinical Trial.
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.
Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, Cornet M, Greene J, Herbrecht R, Lacroix C, Grenouillet F, Raad I, Sitbon K, Troke P; French Mycoses Study Group. Lortholary O, et al. Antimicrob Agents Chemother. 2010 Oct;54(10):4446-50. doi: 10.1128/AAC.00286-10. Epub 2010 Jul 12. Antimicrob Agents Chemother. 2010. PMID: 20625156 Free PMC article.
Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis.
Pang L, Zhao X, Dickens BL, Lim JT, Cook AR, Netea MG, Donnelly JP, Herbrecht R, Johnson EM, Maertens JA, Kullberg BJ, Troke PF, Marr KA, Chai LYA. Pang L, et al. Among authors: troke pf. Clin Microbiol Infect. 2020 Jun;26(6):781.e1-781.e8. doi: 10.1016/j.cmi.2019.10.019. Epub 2019 Oct 24. Clin Microbiol Infect. 2020. PMID: 31669427 Free article. Clinical Trial.
Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis.
Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, Troke PF, Netea MG, Herbrecht R. Chai LY, et al. Among authors: troke pf. J Clin Microbiol. 2012 Jul;50(7):2330-6. doi: 10.1128/JCM.06513-11. Epub 2012 May 2. J Clin Microbiol. 2012. PMID: 22553232 Free PMC article.
47 results